Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides

Regulatory Peptides

Volumn 85, Issue 1, 1999, Pages 9-24

  Mentlein, Rolf ^a  

^a Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

Chemokines; Dipeptidyl peptidase IV (EC 3.4.14.5); Glucagon like peptide 1; Growth hormone releasing hormone; Hormones; Neuropeptides

Indexed keywords

ANTIDIABETIC AGENT; BINDING PROTEIN; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; ENDOMORPHIN 1; ENDOMORPHIN 2; ENZYME INHIBITOR; EOTAXIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE; GROWTH HORMONE RELEASING FACTOR; NEUROPEPTIDE Y; PEPTIDE HORMONE; PEPTIDE YY; RANTES; REGULATOR PROTEIN;

CATALYSIS; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; GLUCOSE TOLERANCE; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, CD26; CATALYSIS; CHEMOKINES; HORMONES; HUMANS; NEUROPEPTIDES; PEPTIDES; TISSUE DISTRIBUTION;

ANIMALIA; MAMMALIA;

EID: 0033619675     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(99)00089-0     Document Type: Review

References (112)

1. Abbott C.A., Baker E., Sutherland G.R., McCaughan G.W. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 40:1994;331-338.
2. Ahmad S., Wang L., Ward P.E. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J. Pharmacol. Exp. Therapeut. 260:1992;1257-1261.
3. Atherton A.J., Monaghan P., Warburton M.J., Robertson D., Kenny A.J., Gusterson B.A. Dipeptidyl peptidase-IV expression identifies a functional sub-population of breast fibroblasts. Int. J. Cancer. 50:1992;15-19.
4. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of proteolytic enzymes. 1998;Academic.
5. Bathon J.M., Proud D., Mizutani S., Ward P.E. Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides. J. Clin. Invest. 90:1992;981-991.
6. Bermpohl F., Löster K., Reutter W., Braun O. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. FEBS Lett. 428:1998;152-156.
7. Bernstein H.G., Schön E., Ansorge S., Röse I., Dorn A. Immunolocalization of dipeptidyl aminopeptidase (DAP IV) in the developing human brain. Int. J. Devel. Neurosci. 5:1987;237-242.
8. Böhm S.K., Gum J.R., Erickson R.H., Hicks J.W., Kim Y.S. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem. J. 311:1995;835-843.
9. Bongers J., Lambros T., Ahmad M., Heimer E.P. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogues. Biochim. Biophys. Acta. 1122:1992;147-153.
10. Boulanger L., Roughly P., Gaudreau P. Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver. Peptides. 13:1992;681-689.
11. Bouras M., Huneau J.F., Luengo C., Erlanson-Albertsson C., Tomé D. Metabolism of enterostatin in rat intestine, brain membranes, and serum: Differential involvement of proline-specific peptidases. Peptides. 16:1995;399-405.
12. Brandsch M., Ganpathy V., Leibach F.H. Role of dipeptidyl peptidase IV (DP IV) in intestinal and renal absorption of peptides. Fleischer B. Dipeptidyl peptidase IV (CD26) in metabolism and the immune response. 1995;111-130 R.G. Landes, Austin.
13. Burcelin R., Dolci W., Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism. 48:1999;252-258.
14. David F., Bernard A.M., Pierres M., Marguet D. Identification of serine624, aspartic acid702, and histidine734 as the catalytic triade residues of mouse dipeptidyl peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases. J. Biol. Chem. 268:1993;17247-17252.
15. Deacon C.F., Hughes T.E., Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 47:1998;764-769.
16. Deacon C.F., Johnson A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
17. Deacon C.F., Knudsen L.B., Madsen K., Wiberg F.C., Jacobsen O., Holst J.J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologica. 41:1998;271-278.
18. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1995;1126-1131.
19. Deacon C.F., Pridal L., Klarskov L., Olesen M., Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 271:1996;E458-E464.
20. Demuth H-U Heins J. Catalytic mechanism of dipeptidyl peptidase I.V. Fleischer B. Dipeptidyl peptidase IV (CD26) in metabolism and the immune response. 1995;1-35 R.G. Landes, Austin.
21. Drucker D.J. Glucagon-like peptides. Diabetes. 47:1998;159-169.
22. Drucker D.J., DeForest L., Brubaker P.L. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am. J. Physiol. 273:1997;G1252-G1262.
23. Drucker D.J., Shi Q., Crivici A., Sumner-Smith M., Tavers W., Hill M., DeForest L., Cooper S., Brubaker P.L. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnol. 15:1997;673-677.
24. Eberlein G.A., Eysselein V.E., Schaeffer M., Layer P., Grandt D., Goebell Niebel W., Davis M., Lee T.D., Shively J.E., Reeve J.R. A new molecular form of PYY: Structural characterization of human PYY(3-36) and PYY(1-36). Peptides. 10:1989;797-803.
25. Fersht A. Enzyme structure and mechanism. 2nd edn. 1985;105-106 W.H. Freeman, New York.
26. Frohman L.A., Downs T.R., Heimer E.P., Felix A.M. Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83:1989;1533-1540.
27. Fujiwara H., Maeda M., Imai, Fukuoka M., Yasuda K., Takakura K. Human luteal cells express dipeptidyl peptidase-IV on the cell surface. J. Clin. Endocrinol. Metabol. 75:1992;1352-1357.
28. Fujiwara T., Tsuji E., Misumii Y., Takami N., Ikehara Y. Selective cell-surface expression of dipeptidyl peptidase IV with mutations at the active site sequence. Biochem. Biophys. Res. Commun. 185:1992;776-784.
29. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., Weinshank R.L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature. 382:1996;168-171.
30. Goldstein L.A., Ghersi G., Pineiro-Sanchez M.L., Salamone M., Yeh Y., Flessate D., Chen W.T. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim. Biophys. Acta. 1361:1997;11-19.
31. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., Reeve J.R. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul. Pept. 51:1994;151-159.
32. Grandt D., Schimiczek M., Rascher W., Feth F., Shively J., Lee T.D., Davis M.T., Reeve J.R., Michel M.C. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul. Pept. 67:1996;33-37.
33. Haninec P., Grim M. Localization of dipeptidyl peptidase IV and alkaline phosphatase in the developing spinal cord meninges and peripheral nerve coverings of the rat. Int. J. Devel. Neurosci. 8:1990;175-180.
34. Heymann E., Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 91:1978;360-364.
35. Heymann E., Mentlein R. Complementary action of dipeptidyl peptidase IV and aminopeptidase M in the digestion of β-casein. J. Dairy Res. 53:1986;229-236.
36. Heymann E., Mentlein R., Nausch I., Erlanson-Albertsson C., Yoshimoto T., Feller A.C. Processing of pro-colipase and trypsinogen by pancreatic dipeptidyl peptidase IV. Biomed. Biochim. Acta. 45:1986;575-584.
37. Hoffmann T., Faust J., Neubert K., Ansorge S. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 336:1993;61-64.
38. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 47:1998;1663-1670.
39. 2-terminal signal/anchor sequence of rat dipeptidyl peptidase IV. J. Cell Biol. 111:1990;323-328.
40. Hopsu-Havu V.K., Glenner G.G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie. 7:1966;197-201.
41. Hupe-Sodmann K., McGregor G.P., Bridenbaugh R., Göke R., Göke B., Thole H., Zimmermann B., Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 58:1995;149-156.
42. Jackman H.L., Tan F.L., Schraufnagel D., Dragovic T., Dezso B., Becker R.P., Erdös E.G. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am. J. Resp. Cell Mol. Biol. 13:1995;196-204.
43. Jacotot E., Callebaut C., Blanco J., Krust B., Neubert K., Barth A., Hovanessian A.G. Dipeptidyl-peptidase IV-beta, novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. Eur. J. Biochem. 239:1996;248-258.
44. Jörnvall H., Carlquist M., Kwauk S., Otte S.C., McIntosh C.H.S., Brown J.C., Mutt V. Amino acid sequence and heterogeneity of the gastric inhibitory polypeptide (GIP). FEBS Lett. 123:1981;205-210.
45. Kato T., Nagatsu T., Fukasawa K., Harada M., Nagatsu I., Sakakibara S. Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl aminopeptidase. Biochim. Biophys. Acta. 525:1978;417-422.
46. Kenny A.J., Hooper N.M. Peptidases involved in the metabolism of bioactive peptides. Henrickson J.H. Degradation of bioactive substances: physiology and pathophysiology. 1991;47-79 CRC, Boca Raton, FL.
47. Kenny A.J., Stephenson S.L., Turner A.J. Cell surface peptidases. Kenny A.J., Turner A.J. Mammalian ectoenzymes. 1987;169-210 Elsevier, Amsterdam.
48. Kettmann U., Humbel B., Holzhausen H.J. Ultrastructural localization of dipeptidyl peptidase-IV in the glomerulum of the rat kidney. Acta Histochem. 92:1992;225-227.
49. Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:1995;3585-3596.
50. Kreil G. Processing of precursors by dipeptidylaminopeptidases: a case of molecular ticketing. Trends Biochem. Sci. 15:1990;23-26.
51. Kubiak T.M., Friedman A.R. Stabilized potent GRF analogs. US Pat. 5756458, May 26. 1998.
52. 2 in bovine and porcine plasma. Correlation with plasma dipeptidyl peptidase activity. Drug Metab Dispos. 17:1989;393-397.
53. Labsch B., Heins J., Hilse H., Barth A., Oehme P. Die Aktivität der Dipeptidyl-Peptidase IV in verschiedenen Geweben der Ratte und ihre mögliche Beziehung zum Substanz-P-Metabolismus. Pharmazie. 36:1981;161-163.
54. de Lecea L., Soriano E., Criado J.R., Steffensen S.C., Henricksen S.J., Sutcliffe J.D. Transcripts encoding a neural membrane CD26 peptidase-like protein are stimulated by synaptic activity. Mol. Brain Res. 25:1994;286-296.
55. Lojda Z. Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase) II Blood vessels. Histochemistry. 59:1979;153-166.
56. Löster K., Zeilinger K., Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD26) is the collagen-binding site. Biochem. Biophys. Res. Commun. 217:1995;341-348.
57. Ludwig R., Feindt J., Lucius R., Petersen A., Mentlein R. Metabolism of neuropeptide Y and calcitonin gene-related peptide by cultivated neurons and glial cells. Mol. Brain. Res. 37:1996;181-191.
58. Martensen I., Koolman J., Mentlein R. A proline-specific dipeptidyl peptidase from flies hydrolyzes the ecdysiostatic peptide Neb-TMOF (trypsin-modulating oostatic factor). Arch Insect Biochem. Physiol. 37:1998;146-157.
59. Martin R.A., Cleary D.L., Guido D.M., Zurcher-Neely H.A., Kubiak T.M. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta. 1164:1993;252-260.
60. McDonald J.K., Barrett A.J. Mammalian proteases: a glossary and bibliography. Vol. 2. Exopeptidases:1986;Academic, London.
61. Mentlein R. Proline residues in the maturation and degradation of peptide hormones and neuropeptides. FEBS Lett. 234:1988;251-256.
62. Mentlein R., Dahms P., Grandt D., Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept. 49:1993;133-144.
63. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:1993;829-835.
64. Mentlein R., Heymann E., Scholz W., Feller A.C., Flad H.-D. Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes. Cell Immunol. 89:1984;11-19.
65. Mentlein R., von Kolszynski M., Sprang R., Lucius R. Proline-specific proteases in cultivated neuronal and glial cells. Brain. Res. 527:1990;159-162.
66. Mentlein R., Roos T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide, and neuropeptide Y by vascular smooth muscle cells. Peptides. 17:1996;709-720.
67. Mentlein R., Staves R., Rix-Matzen H., Tinneberg H.-R. Influence of pregnancy on dipeptidyl peptidase IV activity (CD26 leukocyte differentiation antigen) of circulating lymphocytes. Eur. J. Clin. Chem. Clin. Biochem. 29:1991;477-480.
68. Mentlein R., Struckhoff G. Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J. Neurochem. 52:1989;1284-1293.
69. Mitro A., Lojda Z. Histochemistry of proteases in ependyma, choroid plexus and leptomeninges. Histochemistry. 88:1988;645-646.
70. Misumi Y., Hayashi Y., Arakawa F., Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase-IV, a serine proteinase on the cell surface. Biochim. Biophys. Acta. 1131:1992;333-336.
71. Mochizuki M., Bartels J., Mallet A.I., Christophers E., Schröder J-M. Il-4 induces eotaxin: A possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160:1998;60-68.
72. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 161:1998;55-70.
73. Mussap C.J., Geraghty D.P., Burcher E. Tachykinin receptors: a radioligand binding perspective. J. Neurochem. 60:1993;1987-2009.
74. Nausch I., Mentlein R., Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol. Chem. Hoppe-Seyler. 371:1990;1113-1118.
75. Nilsson C., Westman A., Blennow K., Ekman R. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry. Peptides. 19:1998;1137-1146.
76. Noso N.M., Sticherling J., Bartels A.I., Mallet E., Christophers E., Schröder J.M. Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts. J. Immunol. 156:1996;1946-1953.
77. Ogata S., Misumi Y., Tsuji E., Takami N., Oda K., Ikehara Y. Identification of the active site residues in dipeptidyl peptidase IV by affinity labelling and site-directed mutagenesis. Biochemistry. 31:1992;2582-2587.
78. Ohtsuki T., Hosono O., Kobayashi H., Munakata Y., Souta A., Shioda T., Morimoto C. Negative regulation of the anti-human immunodeficiency virus and chemotatic activity of human stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV. FEBS Lett. 431:1998;236-240.
79. Oravecz T., Pall M., Rodriquez G., Gorrell M.D., Ditto M., Nguyen N.Y., Boykins R., Unsworth E., Norcross M.A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186:1997;1865-1872.
80. Pangalos M.N., Neefs J.M., Somers M., Verhasselt P., Bekkers M., van der Helm L., Fraiponts E., Ashton D., Gordon R.D. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J. Biol. Chem. 274:1999;8470-8483.
81. Pauly R.P., Rosche F., Wermann M., McIntosh C.H.S., Pederson R.A., Demuth H-U. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(3-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted Laser desorption/ionization-time of flight mass spectrometry. J. Biol. Chem. 271:1996;23222-23229.
82. Pederson R.A., White H.A., Schlenzig D., Pauly R.P., McIntosh C.H.S., Demuth H-U. Improved tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1998;1253-1258.
83. Pesquero J.B., Jubilut G.N., Lindsey C.J., Paiva A.C.M. Bradykinin metabolism pathway in the rat pulmonary circulation. J. Hypertens. 10:1992;1471-1478.
84. Proost P., DeMeester I., Schols D., Struyf S., Lambeir A.M., Wuyts A., Opdenakker G., De Clerq E., Scharpe S., Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1 infection. J. Biol. Chem. 273:1998;7222-7227.
85. Proost P., Struyf S., Schols D., Durinx C., Wuyts A., Lenaerts J.P., De Clerq E., De Meester I., Van Damme J. Processing by CD26/dipeptidyl-peptidase I.V. reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett. 432:1998;73-76.
86. Proost P., Struyf S., Schols D., Opdenakker G., Sozzani S., Allavena P., Mantovani A., Augustyns K., Bal G., Haemers A., Lambeir A M., Scharpe S., Van Damme J., De Meester I. Truncation of macrophage-derived chemokine by CD26/dipeptidyl peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. 274:1999;3988-3993.
87. Püschel G., Mentlein R., Heymann E. Isolation and characterization of dipeptidyl peptidase IV from human placenta. Eur. J. Biochem. 126:1982;359-365.
88. Rahfeld J., Schierhorn M., Hartrodt B., Neubert K., Heins J. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim. Biophys. Acta. 1076:1991;314-316.
89. Raynaud F., Bauvois B., Gerbaud P., Evainbrion D. Characterisation of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J. Cell. Physiol. 151:1992;378-385.
90. Russell J.S., Chi H., Lantry L.E., Stephens R.E., Ward P.E. Substance P and neurokinin metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides. 17:1996;1397-1403.
91. Sahara N., Fukasawa K., Harada M., Suzuki K. Immunohistochemical localization of dipeptidyl aminopeptidase (DAP) IV in the rat endocrine organs. Acta Histochem. Cytochem. 14:1981;581-587.
92. Schmidt W.E., Siegel E.G., Kümmel H., Gallwitz B., Creutzfeld W. Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. Endocrinology. 120:1987;835-837.
93. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpe S., Van Damme J., De Clerq E. CD26-processed RANTES(3-36), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res. 39:1998;175-187.
94. Shane R., Wilk S., Bodnar R.J. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res. 815:1999;278-286.
95. Shaw C., Cormican K., Thim L., Maule A.G., Sloan J.M., Buchanan K.D. Neuropeptide Y and neuropeptide Y 3-36: isolation from human pancreatic endocrine tumours. Regul. Pept. 45:1993;387-394.
96. Shioda T., Kato H., Ohnishi Y., Tashiro K., Ikegawa M., Nakayama E.E., Hu H., Kato A., Sakai Y., Liu H., Honjo T., Nomot A., Iwamoto A., Morimoto C., Nagai Y. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. USA. 95:1998;6331-6336.
97. Siegel E.G., Gallwitz B., Scharf G., Mentlein R., Morys-Wortmann C., Fölsch U.R., Schrezenmeir J., Drescher K., Schmidt W.E. Biological activity of GLP-1-analogues with N-terminal modifications. Regul. Pept. 79:1999;93-102.
98. Struyf S., De Meester I., Scharpe S., Lenaerts J.P., Menten P., Wang J.M., Proost P., Van Damme J. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28:1998;1262-1271.
99. 2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J. Immunol. 161:1998;2672-2675.
100. Struyf S., Proost P., Schols D., De Clerq E., Opdenakker G., Lenaerts J.P., Detheux M., Parmentier M., De Meester I., Scharpé S., Van Damme J. CD26/Dipeptidyl peptidase IV down regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 162:1999;4903-4909.
101. Turzynski A., Mentlein R. Prolyl aminopeptidase from rat brain and kidney: action on peptides and identification as leucyl aminopeptidase. Eur. J. Biochem. 190:1990;509-515.
102. von Bonin A., Huhn J., Fleischer B. Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol. Rev. 161:1998;43-53.
103. Van Coillie E., Proost P., Van Aelst I., Struyf S., Polfliet M., De Meester I., Harvey D.J., Van Damme J., Opdenakker G. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry. 37:1998;12672-12680.
104. Vanhoof G., Goossens F., De Meester I., Hendricks D., Scharpe S. Proline motifs in peptides and their biological processing. FASEB J. 9:1995;736-744.
105. Wada K., Yokotani N., Hunter C., Doi K., Wenthold R.J., Shimasaki S. Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci USA. 89:1992;197-201.
106. Wang L., Ahmad S., Benter I F., Chow A., Mizutani S., Ward P.E. Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin-converting enzyme. Peptides. 12:1991;1357-1364.
107. Wang L., Sadhoun E., Stephens R.E., Ward P.E. Metabolism of substance P and neurokinin a by human vascular endothelium and smooth muscle. Peptides. 15:1994;497-503.
108. Watanabe Y., Kojima T., Fuijmoto Y. Deficiency of membrane-bound dipeptidyl aminopeptidase in a certain rat strain. Experientia. 43:1987;400-401.
109. Wrenger S., Reinhold D., Hoffmann T., Kraft M., Frank R., Faust J., Neubert K., Ansorge S. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. FEBS Lett. 383:1996;145-149.
110. 2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur J Biochem. 260:1999;421-429.
111. Yaron A., Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28:1993;31-81.
112. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., Yeh Y., Chen W.T., Kleinman H.K., Grouzmann E., Grant D.S. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83:1998;187-195.